The landscape of sickle cell disease (SCD) care and treatment delivery is changing. With gene therapies gaining approval, longstanding policy inequities receiving attention, and a fragile healthcare infrastructure, this is a time of promise and uncertainty for patients and providers alike.
The Biden-Harris Administration signaled a push toward greater access and equity. At the same time, major setbacks – like the withdrawal of Oxbryta from the market and the cut-price sale of Bluebird Bio – have laid bare the economic and systemic challenges that continue to restrict access to innovative therapies. Now, with the US operating under the Trump-Vance administration, scientific progress is a new issue; as are affordability, logistics, and delivery.
Amid this turbulence, proven—but underused—solutions like automated red blood cell exchange (aRBCX) offer a glimmer of hope. Yet such options remain inconsistently adopted.
This roundtable brings together thought leaders and industry innovators to explore the opportunities and obstacles in reshaping SCD care: What will it take to ensure equitable access to new therapies? How can we better leverage existing technologies? And how can the field maintain momentum when commercial, regulatory, and healthcare realities continue to shift?
Meet the experts:
Koenraad Dierick, Vice President Patient Access, Terumo Blood and Cell Technologies
Jennifer Jones OF THE National Alliance of Sickle Cell Centers
Kevin Wake of the Uriel E. Owens Sickle Cell Disease Association of the Midwest)
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
